Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies

    SOUTH EASTON, Mass., Aug. 20 /EMWNews/ -- Pressure

BioSciences, Inc. (Nasdaq: PBIO) ("PBI" or the "Company") today announced

the release for sale of ProteoSolve-SB, a novel, pressure cycling

technology ("PCT")-dependent kit for the simultaneous extraction,

isolation, and fractionation of nucleic acids (DNA and RNA), proteins, and

lipids from animal and plant samples routinely used in laboratory research.

This patent-pending kit was released earlier this week at the International

HUPO (Human Proteomic Organization) Meeting, being held in Amsterdam, The

Netherlands. It contains proprietary reagents, consumable processing

containers (PULSE Tubes), and instructions for use, and is intended to be

used with the Company's patented PCT Sample Preparation System. The kit is

based on the unique approach to a "systems biology" sample preparation

method that was first unveiled earlier this year by the PBI scientific team

in collaboration with Dr. Alexander Ivanov of the Harvard School of Public

Health at the annual meetings of US HUPO and the Association of

Biomolecular Research Facilities (ABRF).



    Systems biology (SB) is the study of the complex interactions of

biological systems within an organism. This allows the researcher to

consider the integrated effects and emergent properties of many complex

biological systems, which in turn should result in the more rapid

development of diagnostics and therapeutics. Integral to the SB approach is

the study of nucleic acids, proteins, and lipids from the same biological

sample. Very few techniques currently available allow for the efficient

concomitant extraction, isolation, and fractionation of these important

bio-molecules; therefore, scientists must rely on mutually incompatible

sample preparation methods that result in costly, time-consuming, and

problematic processing issues.



    Dr. Vera Gross, Senior Scientist in R&D for PBI, and one of the

inventors of the kit, said: "There are several methods available today that

offer scientists the important ability to get proteins, DNA, and RNA from

the same sample. However, unlike nearly all of these kits, ProteoSolve-SB

does not use inefficient columns or harsh detergents that can cause serious

problems with protein recovery. Instead, ProteoSolve-SB uses organic

solvents that can be easily and quickly removed, and that have been shown

to offer enhanced protein recovery over current methods. Furthermore,

unlike ProteoSolve-SB, none of the methods available today extract lipids

in addition to proteins and nucleic acids from the same biological sample

-- lipid extraction is very important, and integral to a systems biology

approach."



    Mr. Richard T. Schumacher, Founder, President, and CEO of PBI

commented: "Our number one priority is to drive the installed base of PCT

Sample Preparation Systems throughout the life sciences area. We believe

the best way to achieve this goal is to develop PCT-dependent products that

can improve scientific research and enhance the opportunity for discovery.

ProteoSolve-SB, and the recently released FT500-ND PULSE Tube and the

Proteolysis (Trypsin)-PrEP application, were all designed with these

important objectives in mind. To this end, we believe that our

PCT-dependent products have already begun to fill unmet needs in critical,

growing areas of scientific research. This in part accounts for the record

number of installations already achieved in the current quarter, and the

expectation that we will install 40 or more PCT Systems in 2008 as compared

to 20 in 2007, as announced on August 14th."

    About Pressure BioSciences, Inc.



    Pressure BioSciences, Inc. (PBI) is a publicly traded company focused

on the development of a novel, enabling technology called Pressure Cycling

Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient

and ultra-high levels (up to 35,000 psi and greater) to control

bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents

covering multiple applications of PCT in the life sciences field, including

such areas as genomic and proteomic sample preparation, pathogen

inactivation, the control of chemical reactions, immunodiagnostics, and

protein purification.



    Forward Looking Statements



    Statements contained in this press release regarding the Company's

intentions, hopes, beliefs, expectations, or predictions of the future are

"forward-looking" statements within the meaning of the Private Securities

Litigation Reform Act of 1995. Such forward looking statements include

statements regarding the use of the Company's Pressure Cycling Technology

Sample Preparation System (PCT SPS) for the simultaneous extraction,

isolation, and fractionation of nucleic acids, proteins, and lipids from a

wide variety of cells and tissues; that the use of the Company's PCT SPS

with certain proprietary reagents has advantages over other currently

available methods in the extraction of proteins, lipids, and nucleic acids;

that nucleic acids, proteins, and lipids can be partitioned separately in a

single step and that this "systems biology" approach may lead to the

development of important diagnostics and therapeutics; that bio-molecule

extraction by the PCT method is done in a more cost effective, less

time-consuming, and less problematic way; that proteins may be extracted by

the PCT method that may not be extracted by other current techniques; the

expectation that the Company will install a record number of PCT Systems in

the 2008 third quarter and 40 or more during 2008 as compared to 20 in

2007; and the potential markets for the Company's PCT-based products. These

statements are based upon the Company's current expectations, forecasts,

and assumptions that are subject to risks, uncertainties, and other factors

that could cause actual outcomes and results to differ materially from

those indicated by these forward-looking statements. These risks,

uncertainties, and other factors include, but are not limited to:

unforeseen technological difficulties that the Company may encounter in the

development of the PCT technology; due to such unforeseen technical

difficulties, or marketing, sales, and distribution difficulties, the

PCT-dependent systems biology method of bio-molecule extraction may not

offer significant advantages over current methods of bio-molecule

extraction; that the PCT-dependent, systems biology method of bio-molecule

extraction may not be adopted by the scientific community as an accepted

method of bio-molecule extraction, or may not help advance scientific

research, diagnostic development, or drug discovery; that the

PCT-dependent, systems biology method of bio-molecule extraction may not

enable the extraction of any proteins not previously extracted by current

methods; that other scientists who use the PCT-dependent method of

bio-molecule extraction may not achieve the results reported by Dr. Ivanov

and others; and the other risks and uncertainties discussed under the

heading "Risk Factors" in the Company's Annual Report on Form 10-K for the

year ended December 31, 2007 and other reports filed by the Company from

time to time with the SEC. The Company undertakes no obligation to update

any of the information included in this release, except as otherwise

required by law.






    Visit us at our website http://www.pressurebiosciences.com



    Investor Contacts:

    Richard T. Schumacher, President & CEO

    Edward H. Myles, Sr. Vice President of Finance & CFO

    Pressure BioSciences, Inc.

    (508) 230-1828 (T)